70 results about "Total hemoglobin" patented technology

Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.

The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase, and peroxidase. The invention provides kits for performing the methods of the invention.

Systems, methods, and related computer program products for non-invasive NIR spectrophotometric (NIRS) monitoring of total blood hemoglobin levels and/or other blood constituent levels based on a hybrid combination of phase modulation spectrophotometry (PMS) and continuous wave spectrophotometry (CWS) are described. PMS-based measurements including both amplitude and phase information used in the determination of a non-pulsatile component of an absorption property for each of at least three distinct wavelengths are processed to compute PMS-derived intermediate information at least partially representative of a scattering characteristic. CWS-based measurements including amplitude information is processed in conjunction with the PMS-derived intermediate information to compute a pulsatile component of the absorption property. A metric representative of at least one chromophore level, such as the total blood hemoglobin level, is computed from the pulsatile component of the absorption property at the at least three wavelengths and displayed on an output display.

A reaction cassette for a glycated hemoglobin meter and a measuring method thereof are provided. The reaction cassette for the glycated hemoglobin meter includes: a first zone receiving a first reagent and a blood sample; a second zone receiving a second reagent; a reaction zone in which the blood sample reacts with the first reagent, or through which the second reagent passes to react with a first blood sample mixture obtained by reacting the blood sample with the first reagent; and a measurement zone measuring an amount of total hemoglobin in the first blood sample mixture, or measuring an amount of glycated hemoglobin in a second blood sample mixture obtained by reacting the first blood sample mixture with the second reagent, wherein the blood sample, the first reagent, and the second reagent move between the reaction zone and the measurement zone according to a rotation angle of the reaction cassette when the reaction cassette is rotated. Therefore, since the reaction cassette rotates automatically, it is possible to measure the amount of glycated hemoglobin in a blood sample through simple manipulation and reduce a manufacturing time. Furthermore, since reagents are supplied to the reaction cassette from a separate reagent pack, it is possible to resolve storage and distribution problems of the reaction cassette, which occur when reagents are stored in the reaction cassette.

Intra-oral imaging apparatus and/or method embodiments can provide digital dental reflectance images used to identify selected areas of interest (AOI) within a dental region of interest (ROD having selected image characteristics for both hemo-globin's total concentration and oxygenation level. In one embodiment, reflectance images can determine relative total hemoglobin using at least a wavelength band that includes an isobestic wavelength for absorption coefficients of oxyhemoglobin (HbO₂) and deoxyhemoglobin (Hb). In one embodiment, intra-oral imaging apparatus and/or method embodiments can use reflectance images of a dental region at least at three wavelengths; a control logic processor for processing the reflectance images to determine relative tHb and its relative oxygenation level and/or identify disease areas having periodontal tissues condition; and a display for displaying periodontal tissues or a visual indication of the areas having selected imaging characteristic determined by the reflectance images.

The invention relates to a method for measuring glycosylated hemoglobin content, which comprises the following steps of: a, uniformly mixing a whole blood sample and hemolytic liquid; b, adding an appropriate amount of hemolyzed sample into latex suspending in glycine buffer solution; c, respectively adding an antibody B reagent and an antibody A reagent after preset time; d, uniformly mixing andreading a scattering value through a specific protein analyzer under the condition of single-wavelength light irradiation; and e, reading the glycosylated hemoglobin content from a standard curve diagram according to the scattering value. The glycosylated hemoglobin content of the blood sample can be directly determined without separately measuring the total hemoglobin content and the glycosylated hemoglobin content of the blood sample by taking fixed-time nephelometry as a detection principle; and antibody working solution does not need preparing in advance, so that the effective service time of the reagents is prolonged, the operating steps are simplified and the measuring time of the sample is shortened.

The present invention relates to a system for measuring the hemoglobin concentration in whole blood, wherein the system comprises: a light-radiating unit including a light source that emits two types of incident light having different wavelengths; a diffusion unit which diffuses the incident light emitted by the light-radiating unit; a cuvette-holding unit which is formed so as to hold a cuvette including a blood sample; a detection unit which detects each absorbance of the two types of incident light having different wavelengths; a processing unit which determines the hemoglobin concentration in the blood by processing the measured absorbance result; and a control unit which regulates the two types of incident light having different wavelengths in order to repeatedly/sequentially radiate same. Although the system for measuring hemoglobin in whole blood of the present invention uses a small amount of whole blood, it is possible to measure the total hemoglobin concentration in an accurate and reliable manner. The system of the present invention aligns the paths of two types of incident light having different wavelengths passing through a microcuvette by using a diffuser plate so as to easily align a light source and increase the reliability of the results. Also, the system of the present invention uses two wavelengths so as to rapidly and accurately measure the total amount of hemoglobin, including oxidized and reduced hemoglobin.

The present invention relates to a cyanide-free lytic reagent composition and method for measuring the total hemoglobin concentration in a blood sample, for counting the number of leukocytes and for differential counting of three leukocyte subpopulations including lymphocytes, monocytes, and granulocytes. The cyanide-free lytic reagent composition comprises a hemolytic surfactant selected from the group consisting of quaternary ammonium salts, pyridinium salts, organic phosphate esters, and alkyl sulfonates to lyse erythrocytes and release hemoglobin, and an organic ligand selected from the group consisting of triazole and its derivatives, tetrazole and its derivatives, alkaline metal salts of oxonic acid, melamine, aniline-2-sulfonic acid, quinaldic acid, 2-amino-1,3,4-thiadiazole, triazine and its derivatives, urazole, DL-pipecolinic acid, isonicotinamide, anthranilonitrile, 6-aza-2-thiothymine, adenine, 3-(2-thienyl)acrylic acid, benzoic acid and alkali metal and ammonium salts of benzoic acid, and pyrazine and its derivatives to form a stable chromogen with hemoglobin. Alternatively, the organic ligands can be added to a suitable blood diluent for hemoglobin and leukocyte analysis.